Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

D0950000

Diazoxide

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

7-Chloro-3-methyl-2H-1,2,4-benzothiadiazine 1,1-dioxide

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C8H7ClN2O2S
CAS Number:
364-98-7
Molecular Weight:
230.67
MDL number:
MFCD00078578
UNSPSC Code:
41116107
PubChem Substance ID:
329798656
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

diazoxide

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

CC1=Nc2ccc(Cl)cc2S(=O)(=O)N1

InChI

1S/C8H7ClN2O2S/c1-5-10-7-3-2-6(9)4-8(7)14(12,13)11-5/h2-4H,1H3,(H,10,11)

InChI key

GDLBFKVLRPITMI-UHFFFAOYSA-N

Gene Information

human ... KCNJ11(3767) , KCNJ8(3764)

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Diazoxide EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

related product

Product No.
Description
Pricing

Pictograms

Exclamation mark
GHS07

Signal Word

Warning

Hazard Statements

H302,H315,H319,H335

Hazard Classifications

Acute Tox. 4 Oral - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

Target Organs

Respiratory system

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Melissa M Anastacio et al.
The Annals of thoracic surgery, 95(6), 2042-2050 (2013-05-07)
The adenosine triphosphate-sensitive potassium (KATP) channel opener, diazoxide, preserves myocyte volume homeostasis and contractility during stress via an unknown mechanism. Pharmacologic overlap has been suggested between succinate dehydrogenase (SDH) activity and KATP channel modulators. Diazoxide may be cardioprotective due to
William A Coetzee
Pharmacology & therapeutics, 140(2), 167-175 (2013-06-25)
Diazoxide has been identified over the past 50years to have a number of physiological effects, including lowering the blood pressure and rectifying hypoglycemia. Today it is used clinically to treat these conditions. More recently, another important mode of action emerged:
R M Pearson
Clinical pharmacokinetics, 2(3), 198-204 (1977-05-01)
Diazoxide is given by rapid intravenous injection for the urgent reduction of high blood pressure in patients with all grades of renal function. Oral diazoxide produces less consistent effects. Protein binding of diazoxide is reduced in renal failure and this
Melissa M Anastacio et al.
Journal of the American College of Surgeons, 216(6), 1144-1149 (2013-03-29)
Diazoxide maintains myocyte volume and contractility during stress via an unknown mechanism. The mechanism of action may involve an undefined (genotype unknown) mitochondrial ATP-sensitive potassium channel and is dependent on the ATP-sensitive potassium channel subunit sulfonylurea type 1 receptor (SUR1).
Yael Levy-Shraga et al.
Journal of pediatric endocrinology & metabolism : JPEM, 26(3-4), 301-308 (2013-01-19)
Congenital hyperinsulinism (CHI) is the most common cause of persistent hypoglycemia in infants. Its management can be extremely complicated, and may involve medical therapy and surgery. The mainstay of the treatment is to maintain normoglycemia, since hypoglycemia during infancy can
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service